EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

Gerald W Prager, Julien Taieb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Elez, Felipe M Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Pápai, Pierre-Guillaume Poureau, Gabor Liposits und 9 weitere

New England Journal of Medicine · 04.05.2023 · 388 (18) · 1657-1667

DOI: 10.1056/nejmoa2214963 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 04.05.2023. Verfasst von Gerald W Prager und 20 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna (G.W.P.); the Department of Gastroenterology and…. Hauptthemen laut MEDLINE: Colonic Neoplasms, Colorectal Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 481-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Servier, Taiho Oncology, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsColorectal NeoplasmsRectal NeoplasmsAdultHumansAntineoplastic Combined Chemotherapy ProtocolsBevacizumabDrug CombinationsPyrrolidinesTrifluridineUracilThymine

Substanzen

BevacizumabDrug CombinationsPyrrolidinesTrifluridineUraciltipiracilThymine

Autor:innen und Institutionen

  • From the Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna (G.W.P.); the Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, SIRIC Cancer…

ORCID-Profile: Karim A Benhadji

Förderung

  • Servier
  • Taiho Oncology, Inc

Zitieren

APA

Prager, G. W., Taieb, J., Fakih, M., Ciardiello, F., Van Cutsem, E., Elez, E., Cruz, F. M., Wyrwicz, L., Stroyakovskiy, D., Pápai, Z., Poureau, P. G., Liposits, G., Cremolini, C., Bondarenko, I., Modest, D. P., Benhadji, K. A., Amellal, N., Leger, C., Vidot, L., …, & SUNLIGHT Investigators (2023). Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. New England Journal of Medicine, 388(18), 1657-1667. https://doi.org/10.1056/nejmoa2214963

Vancouver

Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, et al. Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. New England Journal of Medicine. 2023;388(18):1657-1667. doi:10.1056/nejmoa2214963

BibTeX
@article{Prager2023,
  author = {Prager, Gerald W and Taieb, Julien and Fakih, Marwan and Ciardiello, Fortunato and Van Cutsem, Eric and Elez, Elena and Cruz, Felipe M and Wyrwicz, Lucjan and Stroyakovskiy, Daniil and Pápai, Zsuzsanna and Poureau, Pierre-Guillaume and Liposits, Gabor and Cremolini, Chiara and Bondarenko, Igor and Modest, Dominik P and Benhadji, Karim A and Amellal, Nadia and Leger, Catherine and Vidot, Loïck and Tabernero, Josep and SUNLIGHT Investigators, SUNLIGHT Investigators},
  title = {Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {18},
  pages = {1657--1667},
  doi = {10.1056/nejmoa2214963}
}
Kostenlos starten →